- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Two roads for oncolytic immunotherapy development ; volume:7 ; number:1 ; day:1 ; month:2 ; year:2019 ; pages:1-5 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (1.2.2019), 1-5, 12.2019
- Creator
-
Kaufman, Howard L.
Bommareddy, Praveen K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0515-2
- URN
-
urn:nbn:de:101:1-2019030823564713906075
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kaufman, Howard L.
- Bommareddy, Praveen K.
- SpringerLink (Online service)
Other Objects (12)
Oncolytic viruses for cancer immunotherapy
Perspectives on immunotherapy via oncolytic viruses
Oncolytic herpes simplex virus and immunotherapy
Oncolytic virus immunotherapy: future prospects for oncology
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Two roads to the successor axiom
Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control
Oncolytic viruses for cancer immunotherapy
Perspectives on immunotherapy via oncolytic viruses
Oncolytic herpes simplex virus and immunotherapy
Oncolytic virus immunotherapy: future prospects for oncology
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Two roads to the successor axiom
Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control
Oncolytic viruses for cancer immunotherapy
Perspectives on immunotherapy via oncolytic viruses
Oncolytic herpes simplex virus and immunotherapy
Oncolytic virus immunotherapy: future prospects for oncology
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Two roads to the successor axiom